July Thirteen (UPI) – The Food and Drug Administration (FDA) on Wednesday issued an emergency use authorization for the Novavax COVID-19 vaccine with protein-based adjuvant.
Novavax’s protein-based adjuvant vaccine is approved for use in others over the age of 18.
Johnson’s Single Dose Vaccine
“The data, from two separate studies involving more than 30,000 participants, demonstrated a composite efficacy of about 90 percent in preventing an infection,” Goldstein said.
The Novavax COVID-19 adjuvant vaccine is given in two number one doses 3 weeks apart. The Japanese government legalized the use of the vaccine produced in the United States in April.
The U. S. Department of Health and Human Servicessaid the Novavax vaccine will be available at no cost to states, jurisdictions, federal spouse pharmacies and qualified gyms.
“With more than two-thirds of the U. S. public, it’s going to be a U. S. citizen. As the U. S. department of the U. S. is fully vaccinated, we want to have a sense of urgency to make sure all other eligible people are vaccinated, especially as the fall approaches,” said Jason Roos, chief operating officer of HHS Coordination Operations and Response.
“This newer vaccine would give other people another option for themselves from serious illnesses or hospitalizations caused by COVID-19. “